These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22771631)

  • 21. A novel series of highly selective inhibitors of MMP-3.
    Whitlock GA; Dack KN; Dickinson RP; Lewis ML
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6750-3. PubMed ID: 18029177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Homology modeling of gelatinase catalytic domains and docking simulations of novel sulfonamide inhibitors.
    Kiyama R; Tamura Y; Watanabe F; Tsuzuki H; Ohtani M; Yodo M
    J Med Chem; 1999 May; 42(10):1723-38. PubMed ID: 10346925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure of recombinant mouse collagenase-3 (MMP-13).
    Botos I; Meyer E; Swanson SM; Lemaître V; Eeckhout Y; Meyer EF
    J Mol Biol; 1999 Oct; 292(4):837-44. PubMed ID: 10525409
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-resolution solution structure of the catalytic fragment of human collagenase-3 (MMP-13) complexed with a hydroxamic acid inhibitor.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Levin JI; Powers R
    J Mol Biol; 2000 Sep; 302(3):671-89. PubMed ID: 10986126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flexibility and variability of TIMP binding: X-ray structure of the complex between collagenase-3/MMP-13 and TIMP-2.
    Maskos K; Lang R; Tschesche H; Bode W
    J Mol Biol; 2007 Mar; 366(4):1222-31. PubMed ID: 17196980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of novel molecular scaffolds for the design of MMP-13 inhibitors: a first round of lead optimization.
    La Pietra V; Marinelli L; Cosconati S; Di Leva FS; Nuti E; Santamaria S; Pugliesi I; Morelli M; Casalini F; Rossello A; La Motta C; Taliani S; Visse R; Nagase H; da Settimo F; Novellino E
    Eur J Med Chem; 2012 Jan; 47(1):143-52. PubMed ID: 22088955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NMR solution structure of the catalytic fragment of human fibroblast collagenase complexed with a sulfonamide derivative of a hydroxamic acid compound.
    Moy FJ; Chanda PK; Chen JM; Cosmi S; Edris W; Skotnicki JS; Wilhelm J; Powers R
    Biochemistry; 1999 Jun; 38(22):7085-96. PubMed ID: 10353819
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
    Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
    J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A combined molecular modeling study on gelatinases and their potent inhibitors.
    Xi L; Du J; Li S; Li J; Liu H; Yao X
    J Comput Chem; 2010 Jan; 31(1):24-42. PubMed ID: 19412908
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinases in mild and severe temporomandibular joint internal derangement synovial fluid.
    Srinivas R; Sorsa T; Tjäderhane L; Niemi E; Raustia A; Pernu H; Teronen O; Salo T
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 May; 91(5):517-25. PubMed ID: 11346728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. QSAR analysis of some 5-amino-2-mercapto-1,3,4-thiadiazole based inhibitors of matrix metalloproteinases and bacterial collagenase.
    Jamloki A; Karthikeyan C; Hari Narayana Moorthy NS; Trivedi P
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3847-54. PubMed ID: 16682189
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors.
    Ma D; Wu W; Yang G; Li J; Li J; Ye Q
    Bioorg Med Chem Lett; 2004 Jan; 14(1):47-50. PubMed ID: 14684295
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
    Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, synthesis and biological evaluation of 5-hydroxy, 5-substituted-pyrimidine-2,4,6-triones as potent inhibitors of gelatinases MMP-2 and MMP-9.
    Nicolotti O; Catto M; Giangreco I; Barletta M; Leonetti F; Stefanachi A; Pisani L; Cellamare S; Tortorella P; Loiodice F; Carotti A
    Eur J Med Chem; 2012 Dec; 58():368-76. PubMed ID: 23149299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetylenic TACE inhibitors. Part 1. SAR of the acyclic sulfonamide hydroxamates.
    Levin JI; Chen JM; Cheung K; Cole D; Crago C; Santos ED; Du X; Khafizova G; MacEwan G; Niu C; Salaski EJ; Zask A; Cummons T; Sung A; Xu J; Zhang Y; Xu W; Ayral-Kaloustian S; Jin G; Cowling R; Barone D; Mohler KM; Black RA; Skotnicki JS
    Bioorg Med Chem Lett; 2003 Aug; 13(16):2799-803. PubMed ID: 12873518
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent, selective pyrimidinetrione-based inhibitors of MMP-13.
    Reiter LA; Freeman-Cook KD; Jones CS; Martinelli GJ; Antipas AS; Berliner MA; Datta K; Downs JT; Eskra JD; Forman MD; Greer EM; Guzman R; Hardink JR; Janat F; Keene NF; Laird ER; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robertson D; Sperger D; Vaughn-Bowser ML; Waller DM; Yocum SA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5822-6. PubMed ID: 16942871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
    Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
    Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orally bioavailable dual MMP-1/MMP-14 sparing, MMP-13 selective alpha-sulfone hydroxamates.
    Kolodziej SA; Hockerman SL; Boehm TL; Carroll JN; DeCrescenzo GA; McDonald JJ; Mischke DA; Munie GE; Fletcher TR; Rico JG; Stehle NW; Swearingen C; Becker DP
    Bioorg Med Chem Lett; 2010 Jun; 20(12):3557-60. PubMed ID: 20529684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Structure-activity relationship of hydroxamate-based inhibitors on membrane-bound Fas ligand and TNF-alpha processing.
    Yamamoto M; Hirayama R; Naruse K; Yoshino K; Shimada A; Inoue S; Kayagaki N; Yagita H; Okumura K; Ikeda S
    Drug Des Discov; 1999 Aug; 16(2):119-30. PubMed ID: 10533808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.